In another study, it was documented that the intravenous administration of MYXV to mice with disseminated myeloma eliminated 70–90% of malignant cells within 24 h and that MYXV also induced CD8+ T-cell responses with potent antimyeloma effects [65]. Here, CD8A is linked to plasma cell myeloma.